NDAC meeting
This article was originally published in The Tan Sheet
Executive Summary
Committee will meet in closed session April 23 to discuss "confidential trade secret information" with FDA and to receive an update from agency's drug review division. One day earlier, NDAC will consider Schering-Plough's three switch NDAs for non-sedating antihistamine Claritin (loratadine); the "primary purpose" of the April 22 meeting is to discuss chronic idiopathic urticaria as an OTC indication, FDA says...